Compare Novo Nordisk A/S (NVO) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance

Novo Nordisk A/STrade

Invesco S&P 500 Momentum ETFTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Invesco S&P 500 Momentum ETF — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Invesco S&P 500 Momentum ETF trades at $150. The key difference: Novo Nordisk A/S pays a 3.63% dividend while Invesco S&P 500 Momentum ETF pays none, and Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.

	NVO	SPMO
Market Cap	$220.53B	—
Sector	Health	Broad Market / Factor
52-Week High	$71.70	$161.66
52-Week Low	$35.29	$107.84
Enterprise Value	$239.49B	—
Dividend Yield	3.63%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

No Aura AI signal available yet.

Invesco S&P 500 Momentum ETF

SPMO trades at $144.50 with a slight 0.42% daily gain. Technical indicators show a bearish trend with moving averages signaling caution, though oscillators are neutral. Recent news highlights strong momentum performance, with the ETF gaining 7.5% in June 2026 and leading S&P factors. The portfolio is concentrated in technology stocks, benefiting from AI-driven growth but facing volatility risks.

Outlook remains mixed; AI momentum supports growth, but high concentration and bearish technicals pose risks. Investors should weigh the ETF's rules-based strategy against potential sector rotations. Dividend of $0.25 is scheduled for June 2026, adding income appeal amid market uncertainty.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVO

Novo Nordisk sues Eli Lilly over misleading GLP-1 drug ads claiming superior weight-loss results.Proactive Investors · 9 hours agoBearish Novo Nordisk sues Eli Lilly over misleading ads on obesity and diabetes drug efficacy.CNBC · 13 hours agoBearish Novo Nordisk shares jump 27% on strong sales of oral Wegovy and market expansion.Seeking Alpha · 1 day agoBullish View details →

SPMO

View details →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

About Invesco S&P 500 Momentum ETF

SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.